Introduction
Sun Pharmaceutical Industries Limited, the world’s leading specialty generic company and India’s largest pharmaceutical manufacturer, published its financial performance for the first quarter ended June 30, 2026 (Q1 FY27). Operating across more than 100 countries, the company’s Q1 FY27 results highlight a strategic shift away from price-sensitive commodity generics toward high-margin, complex peptide products and Global Innovative Medicines.
Despite broader pricing pressures in US generic channels and ongoing regulatory scrutiny, Sun Pharma demonstrated top-line resilience. Growth was driven by outperformance in its home market of India, consistent expansion across Emerging Markets, and ongoing market share gains in its specialty dermatology and ophthalmology portfolios.
┌────────────────────────────────----------------────────────────────────┐
│ SUN PHARMA Q1 FY27 AT A GLANCE │
├────────────────────────────────┬───────────────────────────────────────┤
│ Consolidated Sales │ ₹151,836 Million (+10.1% YoY) │
│ India Formulations │ ₹54,749 Million (+16.0% YoY) │
│ Global Innovative Medicines │ USD 351 Million (+12.8% YoY) │
│ US Formulations │ USD 427 Million (-9.7% YoY) │
│ EBITDA Margin │ 28.9% │
│ Net Cash Position │ USD 3.4 Billion │
└────────────────────────────────┴───────────────────────────────────────┘
Revenue Performance
Consolidated sales for Q1 FY27 totaled ₹151,836 million, representing a 10.1% increase over the ₹137,861 million recorded in Q1 FY26. Total revenue from operations, including other operating income of ₹1,163.3 million, stood at ₹152,998.8 million. Total consolidated income reached ₹160,235.0 million, aided by an Other Income contribution of ₹7,236.2 million.
GEOGRAPHIC SALES BREAKDOWN (Q1 FY27)
India Formulations [36%] ──────────────────────┐
US Formulations [27%] ──────────────────┐ │
Emerging Markets [19%] ──────────────┐ │ │
Rest of World [14%] ──────────┐ │ │ │
API & Others [4%] ──────┐ │ │ │ │
▼ ▼ v ▼ ▼
┌──┬───┬───┬───┬───┐
│ 4│14%│19%│27%│36%│
└──┴───┴───┴───┴───┘
Top-line performance across geographies showed varied trends:
India Formulations
Domestic sales were a key growth driver during the quarter. Formulation sales in India rose 16.0% YoY to ₹54,749 million, representing 36.1% of total consolidated sales. According to Pharmarack MAT June 2026 data, Sun Pharma expanded its market-leading share in the Indian pharma market from 8.2% to 8.5%. Growth was driven by chronic and sub-chronic therapeutic categories, notably Cardiovascular (CVD), Central Nervous System (CNS), and Gastroenterology-Orthopedics. Five new products were launched in the domestic market during Q1 FY27.
US Formulations
Formulation sales in the US declined 9.7% YoY to USD 427 million (representing ₹40,419.1 million), contributing 26.6% to consolidated quarterly sales. The contraction was caused by generic drug price erosion and lower revenue contributions from generic gRevlimid (lenalidomide). However, growth in Global Innovative Medicines (led by Ilumya, Cequa, and Odomzo) helped absorb part of the decline in commodity generics.
Emerging Markets (EM) Formulations
Sales across Emerging Markets expanded 4.2% YoY to USD 311 million (₹29,456.3 million), accounting for 19.4% of total sales. Growth in focus markets—including Romania, Brazil, South Africa, and Mexico—was supported by broader adoption of Sun’s specialty and branded generic portfolio.
Rest of World (RoW) Formulations
Formulation sales across Western Europe, Canada, Japan, Australia, and New Zealand were flat at USD 218 million (₹20,685.8 million) compared to USD 219 million in Q1 FY26, contributing 13.6% to consolidated quarterly sales.
Active Pharmaceutical Ingredients (API)
External API sales grew 10.5% YoY to ₹5,972.3 million. The API segment provides vertical integration support for Sun Pharma’s captive formulation manufacturing while supplying third-party global buyers.
Global Innovative Medicines
Sun Pharma’s Global Innovative Medicines portfolio remains central to its long-term strategy. During Q1 FY27, specialty innovative product sales rose 12.8% YoY to USD 351 million, contributing 21.9% to overall consolidated sales.
Growth was led by key commercial assets:
Ilumya (tildrakizumab-asmn): Used for moderate-to-severe plaque psoriasis. A supplemental application for psoriatic arthritis is pending US FDA review with a PDUFA target action date set for October 2026.
Cequa (cyclosporine ophthalmic solution 0.09%): Sustained volume growth in the dry-eye treatment market.
Odomzo (sonidegib): Continued penetration in advanced basal cell carcinoma treatments.
Leqselvi (deuruxolitinib 8mg): Oral JAK inhibitor targeting severe alopecia areata.
Winlevi (clascoterone cream 1%): Topically applied androgen receptor inhibitor for acne.
Unloxcyt (cosibelimab-ipdl): Anti-PD-L1 antibody expanding the company’s oncology footprint.
Profitability & Margin Analysis
Gross profit for the quarter reached ₹122,238 million, delivering a gross margin of 80.5% compared to 79.6% in Q1 FY26. The 90 basis point gross margin expansion reflects a favorable product mix with higher contributions from domestic formulations and specialty innovative assets.
Consolidated EBITDA rose 2.7% YoY to ₹44,177 million. However, EBITDA margin contracted to 28.9% from 31.1% in Q1 FY26. Margin compression was driven by elevated employee benefit expenses (up 15.2% YoY to ₹32,272.3 million) and higher administrative, legal, and commercial launch investments under Other Expenses (₹48,138.1 million).
EBITDA MARGIN TREND (Q1 FY26 vs Q1 FY27)
Q1 FY26 ────────────────────────────────────────► 31.1%
Q1 FY27 ──────────────────────────────────► 28.9%
Key Driver: Increased SG&A, legal, and new product launch investments.
Exceptional Items Breakdown
Consolidated financial statements reflect an exceptional charge of ₹2,040.9 million (net tax credit of ₹94.3 million) for Q1 FY27:
Organon Acquisition Costs: Transaction and due diligence expenses of ₹1,670.0 million incurred in connection with the pending acquisition of Organon & Co.
New Labour Codes Provision: Incremental employee benefit obligation expenses of ₹370.9 million recognized under India’s unified New Labour Codes framework.
After accounting for exceptional items and tax charges of ₹11,974.4 million, reported Net Profit (PAT) stood at ₹28,948 million. Adjusted Net Profit (excluding exceptional items) increased 3.1% YoY to ₹30,894 million. Reported basic EPS stood at ₹12.1 per share.
Research & Development (R&D) & Pipeline Progress
Total R&D expenditure for Q1 FY27 stood at ₹8,263.5 million (5.4% of total sales), compared to ₹9,028.6 million in Q1 FY26. Revenue R&D expense accounted for ₹8,076.6 million. Crucially, 30% of total R&D spend was allocated toward novel, innovative drug development.
INNOVATIVE R&D PIPELINE
┌───────────────┬─────────────────────────────┬─────────────────────────────┐
│ Candidate │ Indication │ Development Stage │
├───────────────┼─────────────────────────────┼─────────────────────────────┤
│ Ilumya │ Psoriatic Arthritis │ US FDA Supplemental Filed │
│ Fibromun │ Soft Tissue Sarcoma / Glio │ Phase 2 Complete / Phase 2 │
│ GL0034 │ Type 2 Diabetes (GLP-1) │ Phase 2 (Topline 2HCY27) │
│ Nidlegy │ Locally Advanced Melanoma │ EMA Regulatory Filing │
│ MM-II │ Osteoarthritis Pain │ Phase 2 Complete (Partnering)│
└───────────────┴─────────────────────────────┴─────────────────────────────┘
Generic Abbreviated New Drug Application (ANDA) Status
During Q1 FY27, Sun Pharma filed 3 ANDAs with the US FDA and received 6 ANDA approvals. Cumulatively, the company holds approvals for 558 ANDAs while 119 ANDAs await US FDA clearance (including 28 tentative approvals). It also maintains 57 approved New Drug Applications (NDAs) with 13 NDAs awaiting approval.
Corporate Updates & Inorganic Growth: Organon Acquisition
On April 27, 2026, Sun Pharma entered into a definitive agreement to acquire all outstanding shares of Organon & Co. for USD 14.00 per share in an all-cash transaction. The deal values Organon at an enterprise value of approximately USD 11.75 billion.
Key transaction milestones:
Organon shareholders approved the transaction on July 23, 2026.
Regulatory approvals under the US Hart-Scott-Rodino (HSR) Act and several foreign jurisdictions have been received.
Both companies will operate as independent entities pending final regulatory clearances, with an Integration Management Office (IMO) actively planning post-closing steps.
Transaction closure is expected in Q4 FY27.
Financial Tables
Table 1: Consolidated Income Statement Summary
(All figures in ₹ Million, except Per Share Data)
| Metric | Q1 FY27 (Unaudited) | Q1 FY26 (Unaudited) | YoY Growth (%) | Q4 FY26 (Audited) |
Revenue from Operations | 152,998.8 | 138,514.0 | +10.46% | 146,117.9 |
Total Sales | 151,835.5 | 137,860.7 | +10.14% | 145,597.5 |
Other Income | 7,236.2 | 4,644.6 | +55.80% | 4,585.0 |
Gross Profit | 122,238.0 | 109,713.0 | +11.42% | 117,586.0 |
Gross Profit Margin (%) | 80.5% | 79.6% | +90 bps | 80.8% |
EBITDA | 44,177.0 | 43,017.0 | +2.70% | – |
EBITDA Margin (%) | 28.9% | 31.1% | -220 bps | – |
Finance Costs | 996.7 | 748.0 | +33.25% | 858.9 |
Depreciation & Amortisation | 7,387.2 | 7,005.5 | +5.45% | 7,754.7 |
Exceptional Items (Charge) | 2,040.9 | 8,180.0 | -75.05% | 0.0 |
Profit Before Tax (PBT) | 40,988.1 | 31,727.7 | +29.19% | 35,513.4 |
Tax Expense | 11,880.1 | 8,701.5 | +36.53% | 8,276.2 |
Reported Net Profit (PAT) | 28,947.9 | 22,786.3 | +27.04% | 27,140.3 |
Adjusted Net Profit | 30,894.0 | 29,961.0 | +3.11% | – |
Basic EPS (₹) | 12.1 | 9.5 | +27.37% | 11.3 |
Table 2: Segment-Wise Formulation & API Sales Breakdown
| Segment | Q1 FY27 (₹ Mn) | Q1 FY26 (₹ Mn) | YoY Growth (%) | Share of Sales (%) |
India Formulations | 54,748.9 | 47,211.0 | +16.0% | 36.1% |
US Formulations | 40,419.1 | 40,452.1 | -0.1% (in ₹) / -9.7% (in USD) | 26.6% |
Emerging Markets | 29,456.3 | 25,531.4 | +15.4% (in ₹) / +4.2% (in USD) | 19.4% |
Rest of World (RoW) | 20,685.8 | 18,735.9 | +10.4% (in ₹) / -0.5% (in USD) | 13.6% |
Total Formulations | 145,310.1 | 131,930.4 | +10.1% | 95.7% |
API | 5,972.3 | 5,403.7 | +10.5% | 3.9% |
Others | 553.1 | 526.6 | +5.0% | 0.4% |
Total Sales | 151,835.5 | 137,860.7 | +10.1% | 100.0% |
Table 3: Standalone Financial Summary
(All figures in ₹ Million)
| Parameter | Q1 FY27 (Unaudited) | Q1 FY26 (Unaudited) | YoY Growth (%) |
Revenue from Operations | 57,411.3 | 55,948.8 | +2.61% |
Total Income | 58,813.0 | 56,985.9 | +3.21% |
R&D Expense | 4,635.9 | 6,146.9 | -24.58% |
Profit Before Tax (PBT) | 14,864.5 | 11,762.6 | +26.37% |
Net Profit (PAT) | 11,151.4 | 7,450.6 | +49.67% |
Management Commentary
Kirti Ganorkar, Managing Director of Sun Pharmaceutical Industries Limited, stated:
“Our performance during the quarter was driven by strong momentum in India as well as Innovative Medicines, which delivered robust growth across the U.S. and international regions. Recent semaglutide approvals in India, Brazil and South Africa underscore our capabilities in developing complex peptide products for patients globally. Organon shareholders have approved the proposed acquisition by Sun, which is on track to close in early 2027.”
Management highlighted that despite competitive pressures in US generics, the company’s specialty portfolio expansion, domestic market leadership, and strong net cash balance of USD 3.4 billion provide a solid foundation for sustainable growth.
Explanation of Results
Higher India Sales (+16%) ──┐
Specialty Growth (+12.8%) ──┼──► Q1 FY27 Net Profit: ₹2,895 Crore
US Generic Drag (-9.7%) ──┤
Lower R&D Intensity (5.4%) ──┘
Why India Sales Surged: Outperformed the broader Indian Pharma Market (IPM) due to dominant prescription share across chronic therapies (Cardiovascular, CNS, and Gastro-Ortho).
Why US Revenues Declined: Sustained price erosion in commodity oral solid generics and lower gRevlimid sales volumes weighed on North American revenues.
Why EBITDA Margins Contracted: High SG&A investments tied to specialty brand marketing, legal fees, and Organon acquisition due diligence reduced EBITDA margin by 220 bps YoY to 28.9%.
Impact of Semaglutide Approvals: Approvals for generic/branded semaglutide in India, Brazil, and South Africa position Sun Pharma to capture share in the expanding global metabolic and diabetes space.
Industry Analysis
Indian Pharmaceutical Industry (IPM)
The Indian pharmaceutical market continues to grow at 8–10% annually, driven by chronic therapy demand, rising healthcare expenditure, and broader insurance coverage. Sun Pharma remains the market leader with an 8.5% market share.
US Generic & Specialty Landscape
The US generic market faces persistent structural price erosion and regulatory scrutiny. In response, Indian drugmakers are shifting capital toward specialty pharmaceuticals, complex injectables, and biosimilars. Sun Pharma’s early transition toward innovative medicines (which now account for ~22% of total sales) provides a competitive buffer against generic price deflation.
Competitor Comparison
INDIAN PHARMA COMPETITOR LANDSCAPE (Q1 FY27)
┌───────────────────┬───────────────────┬───────────────────┐
│ Sun Pharma │ Dr. Reddy's │ Cipla │
│ Sales: ₹15,184 Cr │ Specialty Focus │ Respiratory Focus │
│ India Share: 8.5% │ US Generics Lead │ India Share: ~5.3%│
└───────────────────┴───────────────────┴───────────────────┘
| Company Name | Revenue (Q1 FY27 Est) | EBITDA Margin (%) | Primary Focus Area | Key Advantage |
Sun Pharma | ₹15,184 Cr | 28.9% | Specialty & Domestic | India No. 1, USD 3.4B Net Cash |
| Dr. Reddy’s | ~₹7,600 Cr | ~26.5% | US Generics & Biosimilars | Global Generic Pipeline |
| Cipla | ~₹6,900 Cr | ~24.5% | Domestic & Respiratory | Inhalation Leadership |
| Lupin | ~₹5,400 Cr | ~20.0% | Complex Injectables & US | Respiratory Portfolio |
| Torrent Pharma | ~₹3,100 Cr | ~31.0% | India & Brazil Branded | High Margin Domestic Focus |
Investment Analysis
Bull Case
Specialty Portfolio Scale: Global Innovative Medicines revenue expanded 12.8% YoY to USD 351 million, insulating earnings from generic price erosion.
Domestic Dominance: India business grew 16% YoY with market share expanding to 8.5%.
Balance Sheet Strength: Maintains a net cash position of USD 3.4 billion, supporting R&D investments and capital allocation.
Organon Acquisition Catalysts: The proposed USD 11.75 billion acquisition adds an established global women’s health and biosimilars commercial footprint.
Bear Case
US Generic Headwinds: US formulation sales fell 9.7% YoY amid price deflation.
Regulatory Risks: Ongoing US FDA oversight across manufacturing facilities could delay new ANDA clearances.
Margin Pressure: SG&A investments and transaction costs may compress near-term EBITDA margins.
Valuation & Investment View
VALUATION SUMMARY
┌─────────────────────────────────┬─────────────────────────────────┐
│ Metric │ Value / Assessment │
├─────────────────────────────────┼─────────────────────────────────┤
│ Trailing P/E Multiple │ ~34.5x │
│ Price-to-Book (P/B) │ ~4.8x │
│ EV/EBITDA │ ~22.0x │
│ Valuation Assessment │ Fairly Valued / Premium Quality │
└─────────────────────────────────┴─────────────────────────────────┘
Long-Term Investors: BUY / HOLD — Supported by domestic market leadership, expanding specialty revenue (~22% of total sales), and a net cash balance sheet.
New Investors: ACCUMULATE ON DIPS — High valuation multiples (~34x P/E) suggest pacing entries around market consolidations ahead of the Organon acquisition closing in Q4 FY27.
Future Outlook
Sun Pharma’s long-term growth is anchored by three pillars:
Sustaining Domestic Leadership: Expanding chronic therapy prescriber coverage in India.
Specialty Pipeline Execution: Securing FDA approval for Ilumya in psoriatic arthritis and progressing GL0034 (GLP-1) clinical trials.
Closing the Organon Transaction: Executing post-merger integration to expand its commercial presence across international markets.
Risks
US FDA Regulatory Actions: Facility inspections or import alerts could disrupt supply chains.
Complex Clinical Trial Delays: Phase 2 and Phase 3 trial delays for late-stage assets (e.g., Fibromun, GL0034) could defer future revenues.
Foreign Currency Volatility: FX fluctuations in Emerging Markets may impact translated earnings.
Conclusion
Sun Pharmaceutical Industries Ltd.’s Q1 FY27 financial results show a business transitioning toward specialty pharmaceuticals. While US generic erosion persists, 16% domestic growth and 12.8% growth in Global Innovative Medicines supported top-line expansion. Supported by a USD 3.4 billion net cash balance and the pending Organon acquisition, Sun Pharma remains well positioned in the global pharmaceutical market.
